Literature DB >> 10339480

Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells.

W Piacibello1, F Sanavio, A Severino, A Danè, L Gammaitoni, F Fagioli, E Perissinotto, G Cavalloni, O Kollet, T Lapidot, M Aglietta.   

Abstract

Understanding the repopulating characteristics of human hematopoietic stem/progenitor cells is crucial for predicting their performance after transplant into patients receiving high-dose radiochemotherapy. We have previously reported that CD34(+) cord blood (CB) cells can be expanded in vitro for several months in serum containing culture conditions. The use of combinations of recombinant early acting growth factors and the absence of stroma was essential in determining this phenomenon. However, the effect of these manipulations on in vivo repopulating hematopoietic cells is not known. Recently, a new approach has been developed to establish an in vivo model for human primitive hematopoietic precursors by transplanting human hematopoietic cells into sublethally irradiated nonobese diabetic severe combined immunodeficient (NOD/SCID) mice. We have examined here the expansion of cells, CD34(+) and CD34(+)38(-) subpopulations, colony-forming cells (CFC), long-term culture initiating cells (LTC-IC) and the maintenance or the expansion of SCID-repopulating cells (SRC) during stroma-free suspension cultures of human CD34(+) CB cells for up to 12 weeks. Groups of sublethally irradiated NOD/SCID mice were injected with either 35,000, 20,000, and 10,000 unmanipulated CD34(+) CB cells, which were cryopreserved at the start of cultures, or the cryopreserved cells expanded from 35,000, 20,000, or 10,000 CD34(+) cells for 4, 8, and 12 weeks in the presence of a combination of early acting recombinant growth factors (flt 3/flk2 ligand [FL] + megakaryocyte growth and development factor [MGDF] +/- stem cell factor [SCF] +/- interleukin-6 [IL-6]). Mice that had been injected with >/=20,000 fresh or cryopreserved uncultured CD34(+) cells did not show any sign or showed little engraftment in a limited number of animals. Conversely, cells that had been generated by the same number of initial CD34(+) CB cells in 4 to 10 weeks of expansion cultures engrafted the vast majority of NOD/SCID mice. The level of engraftment, well above that usually observed when the same numbers of uncultured cells were injected in the same recipients (even in the presence of irradiated CD34(-) cells) suggested that primitive hematopoietic cells were maintained for up to 10 weeks of cultures. In addition, dilution experiments suggest that SRC are expanded more than 70-fold after 9 to 10 weeks of expansion. These results support and extend our previous findings that CD34(+) CB stem cells (identified as LTC-IC) could indeed be grown and expanded in vitro for an extremely long period of time. Such information may be essential to design efficient stem cell expansion procedures for clinical use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10339480

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Umbilical cord blood: an expandable resource.

Authors:  M A Moore
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors.

Authors:  Neil C Josephson; George Vassilopoulos; Grant D Trobridge; Greg V Priestley; Brent L Wood; Thalia Papayannopoulou; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

3.  Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells.

Authors:  Kohshi Ohishi; Barbara Varnum-Finney; Irwin D Bernstein
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 4.  Cord blood stem cells for hematopoietic transplantation.

Authors:  Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 5.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 6.  Introduction to next generation of endothelial progenitor cell therapy: a promise in vascular medicine.

Authors:  Dewi Sukmawati; Rica Tanaka
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

7.  Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice.

Authors:  Sara L Rohrabaugh; Timothy B Campbell; Giao Hangoc; Hal E Broxmeyer
Journal:  Blood Cells Mol Dis       Date:  2011-04-15       Impact factor: 3.039

8.  Expansion of human SCID-repopulating cells under hypoxic conditions.

Authors:  Guénahel H Danet; Yi Pan; Jennifer L Luongo; Dominique A Bonnet; M Celeste Simon
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse.

Authors:  Sangeetha V M; V M Sangeetha; Vaijayanti P Kale; Lalita S Limaye
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

10.  The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells.

Authors:  Anthony M Ford; Chiara Palmi; Clara Bueno; Dengli Hong; Penny Cardus; Deborah Knight; Giovanni Cazzaniga; Tariq Enver; Mel Greaves
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.